Drug - Gilotrif™ (afatinib) [Boehringer Ingelheim Pharmaceuticals, Inc.]
Therapeutic area - Metastatic non-small cell lung cancer (NSCLC)
Quantity limit = 30 tablets per 30 days (all strengths)
GILOTRIF™ is indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test. Safety and efficacy of GILOTRIF™ have not been established in patients whose tumors have other EGFR mutations.
MHCP Provider Call Center 651-431-2700 or 800-366-5411